Streamline Your Vaccine Development with CleanCap® AU for Alphavirus RNA Replicons
Unlock the power of self-amplifying RNA replicons for vaccine and therapeutic development with TriLink’s CleanCap® AU technology. This innovative co-transcriptional capping strategy is designed to address the unique challenges of producing self-replicating RNAs based on alphavirus genomes, offering a more efficient and scalable solution compared to traditional capping methods.
Why Choose CleanCap® AU?
TriLink’s CleanCap AU is a cutting-edge nucleotide trimer (m7GpppAmU) that efficiently adds a Cap-1 structure to RNA during transcription. This cap structure is vital for ensuring the stability, translation, and replication of alphavirus-based self-amplifying RNA (saRNA) vaccine candidates. CleanCap® AU offers several advantages over older capping technologies, such as ARCA and enzymatic capping, to ensure optimal results in vaccine development.
Key Advantages of CleanCap® AU Technology
- Enhanced Immunogenicity
CleanCap AU generates a Cap-1 structure, which is recognized as “self” by host cells, reducing unwanted immune responses and promoting efficient translation and replication. - Higher Yields, Greater Efficiency
CleanCap® AU achieves >9 mg/mL transcription yields and ≥95% capping efficiency, compared to lower yields with ARCA and enzymatic capping methods. This allows for more scalable and cost-effective manufacturing. - Improved Structural Integrity
Unlike enzymatic capping, CleanCap AU avoids the structural challenges posed by secondary structures at the RNA 5′ end, ensuring high-quality RNA production without degradation. - Single-Step Co-Transcriptional Capping
CleanCap AU’s one-step co-transcriptional capping process simplifies RNA production, saving time and resources compared to multi-step enzymatic capping systems.
Perfect for Alphavirus-Based saRNA Vaccines
Alphaviruses like Venezuelan equine encephalitis virus (VEEV), Semliki Forest virus (SFV), and Sindbis virus (SIN) provide ideal backbones for saRNA vaccines due to their ability to self-replicate inside host cells. CleanCap® AU ensures that your saRNA vaccines have the proper 5′ AU initiation sequence needed for efficient viral replication, enhancing vaccine effectiveness even at low doses.
Ideal for Rapid, Scalable Vaccine Production
Self-amplifying RNAs offer a modular platform for fast and flexible vaccine development. Whether you’re developing personalized cancer vaccines or targeting novel infectious diseases, CleanCap® AU ensures you can quickly produce high-quality RNA for clinical trials and commercial production.
Comparing Capping Methods for saRNA Vaccines
| Capping Method | Capping Efficiency | Transcription Yield | Challenges |
|---|---|---|---|
| CleanCap AU | ≥95% | >9 mg/mL | Optimized for alphavirus saRNA, no competition with GTP, reduces immune reactogenicity. |
| ARCA | ~70% | ~6 mg/mL | Capping begins with GTP, leading to a Cap-0 structure, suboptimal for eukaryotic translation. |
| Enzymatic Capping | Variable | ~4-5 mg/mL | Multi-step process, time-consuming, sensitive to RNA secondary structure and degradation. |
This article is posted at trilinkbiotech.com
Please fill out the form to access the content